Solid Biosciences Inc. SLDB
We take great care to ensure that the data presented and summarized in this overview for Solid Biosciences Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SLDB
View allLatest Institutional Activity in SLDB
Top Purchases
Top Sells
About SLDB
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at SLDB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 03
2024
|
Jessie Hanrahan Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
4,610
-24.46%
|
$23,050
$5.6 P/Share
|
|
Dec 03
2024
|
Alexander Cumbo President and CEO |
SELL
Open market or private sale
|
Direct |
11,114
-22.41%
|
$55,570
$5.6 P/Share
|
|
Dec 03
2024
|
David T Howton Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
5,072
-24.46%
|
$25,360
$5.6 P/Share
|
|
Dec 03
2024
|
Paul Herzich Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,777
-18.56%
|
$13,885
$5.6 P/Share
|
|
Dec 02
2024
|
Jessie Hanrahan Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,862
+38.63%
|
-
|
|
Dec 02
2024
|
Alexander Cumbo President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
28,612
+36.58%
|
-
|
|
Dec 02
2024
|
David T Howton Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,051
+38.63%
|
-
|
|
Dec 02
2024
|
Paul Herzich Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,239
+32.61%
|
-
|
|
Oct 21
2024
|
Gabriel Brooks Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,923
-21.03%
|
$17,538
$6.5 P/Share
|
|
Oct 18
2024
|
Gabriel Brooks Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,750
+41.22%
|
-
|
|
Oct 03
2024
|
Ian F Smith |
BUY
Exercise of conversion of derivative security
|
Direct |
3,255
+2.88%
|
-
|
|
Jul 03
2024
|
Ian F Smith |
BUY
Exercise of conversion of derivative security
|
Direct |
3,255
+2.97%
|
-
|
|
Jun 07
2024
|
Clare Kahn |
BUY
Open market or private purchase
|
Direct |
1,100
+50.0%
|
$7,700
$7.67 P/Share
|
|
May 02
2024
|
Ilan Ganot |
SELL
Open market or private sale
|
Indirect |
462
-4.63%
|
$4,620
$10.33 P/Share
|
|
May 02
2024
|
Ilan Ganot |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,553
+13.48%
|
-
|
|
Apr 03
2024
|
Ian F Smith |
BUY
Exercise of conversion of derivative security
|
Direct |
3,256
+3.06%
|
-
|
|
Jan 29
2024
|
Ilan Ganot |
SELL
Open market or private sale
|
Indirect |
139
-1.62%
|
$973
$7.99 P/Share
|
|
Jan 27
2024
|
Ilan Ganot |
BUY
Exercise of conversion of derivative security
|
Direct |
3,883
+3.93%
|
-
|
|
Jan 27
2024
|
Ilan Ganot |
BUY
Exercise of conversion of derivative security
|
Indirect |
388
+4.34%
|
-
|
|
Jan 11
2024
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
3,410,713
+33.29%
|
$17,053,565
$5.53 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 4.32M shares |
|---|---|
| Exercise of conversion of derivative security | 116K shares |
| Grant, award, or other acquisition | 1.81M shares |
| Open market or private sale | 32.2K shares |
|---|